title: Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations.
abstract: On each of 10 patients with untreated plaque psoriasis, two symmetrical plaques were injected with cyclosporin A or placebo on six occasions over 12 days, in a double-blind manner. Biopsies taken from these lesions at 14 days were examined for differences in cellular composition using a double-labelling immunofluorescent technique. The cyclosporin-injected plaques cleared significantly better than those injected with placebo (P less than 0.001). In the epidermis of the cyclosporin-injected plaques, total and HLA-DR+ CD4+ and CD8+ T cell numbers were significantly decreased compared to corresponding plaques treated with placebo (total CD4+, total CD8+, DR+ CD4+, P less than 0.01; DR+ CD8+, P less than 0.02). Similarly, T lymphocyte numbers in the dermis were decreased in the cyclosporin compared to placebo-treated plaques; the reduction in total CD4+ and DR+ CD8+ T cell numbers was statistically significant (P less than 0.05). Although total numbers of epidermal dendritic cells were not significantly altered, the DR+CD1- dendritic cell subpopulation was markedly decreased (P less than 0.01) and DR-CD1+ dendritic cells increased (P less than 0.05) in the plaques injected with cyclosporin compared to corresponding placebo-treated plaques. These findings show that cyclosporin injected in situ is effective in clearing psoriasis and probably exerts this beneficial effect by its action on T lymphocytes. A suitable topical preparation that allows penetration of the drug should prove helpful in the treatment of psoriasis.
authors: Department of Immunology, St. Mary's Hospital Medical School, London, U.K.
authors: B S
authors: BS
authors: Baker
authors: A V
authors: AV
authors: Powles
authors: C R
authors: CR
authors: Savage
authors: J P
authors: JP
authors: McFadden
authors: H
authors: H
authors: Valdimarsson
authors: L
authors: L
authors: Fry
mesh_terms: D000328:Adult; D000368:Aged; D002452:Cell Count; D003524:Cyclosporins / Q000008:administration & dosage* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000187:drug effects*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects*
chemical_list: D003524:Cyclosporins